| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Other Original Studies |
Department of Molecular Pharmacology (O.D., N.C.), Albert Einstein College of Medicine, Bronx, New York 10461; Department of Pathology (Z.Ba., V.L.), University of Pennsylvania, Philadelphia, Pennsylvania 19104; and Department of Pathology (Z.Bá.), Faculty of Health Sciences of the Semmelweis University, Budapest, Hungary
Address correspondence to: Nancy Carrasco, M.D., Department of Molecular Pharmacology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, F-209, Bronx, New York 10461.
Abstract
Here we report the analysis of the Na+/I-
symporter (NIS) protein expression in 57 thyroid cancer samples by
immunohistochemistry with high-affinity anti-NIS Abs. As many as 70%
of these samples exhibited increased NIS expression with respect to the
normal surrounding thyroid tissue. Most significantly, NIS was located
in these samples either in both the plasma membrane and intracellular
compartments simultaneously, or exclusively in intracellular
compartments. This suggests that NIS is clearly expressed or even
overexpressed in most thyroid cancer cells, but malignant
transformation in some of these cells interferes either with the proper
targeting of NIS to the plasma membrane, or with the mechanisms that
retain NIS in the plasma membrane after it has been targeted. The
results further indicate that, in addition to indicating NIS expression
in cases where it is absent (
30%), improvements in 131I
radioablation therapy might result from promoting targeting of NIS to
the plasma membrane in the majority (70%) of thyroid cancers.
This article has been cited by other articles:
 |
|
 |
|
  G. Riesco-Eizaguirre, I. Rodriguez, A. De la Vieja, E. Costamagna, N. Carrasco, M. Nistal, and P. Santisteban The BRAFV600E Oncogene Induces Transforming Growth Factor {beta} Secretion Leading to Sodium Iodide Symporter Repression and Increased Malignancy in Thyroid Cancer Cancer Res., November 1, 2009; 69(21): 8317 - 8325. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. E. Smith, M. L. Read, A. S. Turnell, R. J. Watkins, J. C. Watkinson, G. D. Lewy, J. C. W. Fong, S. R. James, M. C. Eggo, K. Boelaert, et al. A novel mechanism of sodium iodide symporter repression in differentiated thyroid cancer J. Cell Sci., September 15, 2009; 122(18): 3393 - 3402. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Peyrottes, V. Navarro, A. Ondo-Mendez, D. Marcellin, L. Bellanger, R. Marsault, S. Lindenthal, F. Ettore, J. Darcourt, and T. Pourcher Immunoanalysis indicates that the sodium iodide symporter is not overexpressed in intracellular compartments in thyroid and breast cancers Eur. J. Endocrinol., February 1, 2009; 160(2): 215 - 225. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Kogai, S. Sajid-Crockett, L. S Newmarch, Y.-Y. Liu, and G. A Brent Phosphoinositide-3-kinase inhibition induces sodium/iodide symporter expression in rat thyroid cells and human papillary thyroid cancer cells J. Endocrinol., November 1, 2008; 199(2): 243 - 252. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. K. M. B. Sodre, I. G. S. Rubio, A. L. R. Galrao, M. Knobel, E. K. Tomimori, V. A. F. Alves, C. T. Kanamura, C. A. Buchpiguel, T. Watanabe, C. U. M. Friguglietti, et al. Association of Low Sodium-Iodide Symporter Messenger Ribonucleic Acid Expression in Malignant Thyroid Nodules with Increased Intracellular Protein Staining J. Clin. Endocrinol. Metab., October 1, 2008; 93(10): 4141 - 4145. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Eszlinger, K. Krohn, S. Hauptmann, H. Dralle, T. J. Giordano, and R. Paschke Perspectives for Improved and More Accurate Classification of Thyroid Epithelial Tumors J. Clin. Endocrinol. Metab., September 1, 2008; 93(9): 3286 - 3294. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y Liu, H. Morreau, J. Kievit, J. A Romijn, N. Carrasco, and J. W Smit Combined immunostaining with galectin-3, fibronectin-1, CITED-1, Hector Battifora mesothelial-1, cytokeratin-19, peroxisome proliferator-activated receptor-{gamma}, and sodium/iodide symporter antibodies for the differential diagnosis of non-medullary thyroid carcinoma Eur. J. Endocrinol., March 1, 2008; 158(3): 375 - 384. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Rhoden, S. Cianchetta, V. Stivani, C. Portulano, L. J. V. Galietta, and G. Romeo Cell-based imaging of sodium iodide symporter activity with the yellow fluorescent protein variant YFP-H148Q/I152L Am J Physiol Cell Physiol, February 1, 2007; 292(2): C814 - C823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Riesco-Eizaguirre and P. Santisteban A perspective view of sodium iodide symporter research and its clinical implications. Eur. J. Endocrinol., October 1, 2006; 155(4): 495 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T Kogai, K Taki, and G A Brent Enhancement of sodium/iodide symporter expression in thyroid and breast cancer. Endocr. Relat. Cancer, September 1, 2006; 13(3): 797 - 826. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Blaser, S. Maschauer, T. Kuwert, and O. Prante In Vitro Studies on the Signal Transduction of Thyroidal Uptake of 18F-FDG and 131I-Iodide J. Nucl. Med., August 1, 2006; 47(8): 1382 - 1388. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Paroder, S. R. Spencer, M. Paroder, D. Arango, S. Schwartz Jr., J. M. Mariadason, L. H. Augenlicht, S. Eskandari, and N. Carrasco Na+/monocarboxylate transport (SMCT) protein expression correlates with survival in colon cancer: Molecular characterization of SMCT PNAS, May 9, 2006; 103(19): 7270 - 7275. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Y Liu, M. P Stokkel, A. M Pereira, E. P Corssmit, H. A Morreau, J. A Romijn, and J. W A Smit Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma. Eur. J. Endocrinol., April 1, 2006; 154(4): 525 - 531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G Riesco-Eizaguirre, P Gutierrez-Martinez, M A Garcia-Cabezas, M Nistal, and P Santisteban The oncogene BRAF V600E is associated with a high risk of recurrence and less differentiated papillary thyroid carcinoma due to the impairment of Na+/I- targeting to the membrane. Endocr. Relat. Cancer, March 1, 2006; 13(1): 257 - 269. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Ma, A. Kuang, J. Xie, and T. Ma Possible Explanations for Patients with Discordant Findings of Serum Thyroglobulin and 131I Whole-Body Scanning J. Nucl. Med., September 1, 2005; 46(9): 1473 - 1480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Krohn, D. Fuhrer, Y. Bayer, M. Eszlinger, V. Brauer, S. Neumann, and R. Paschke Molecular Pathogenesis of Euthyroid and Toxic Multinodular Goiter Endocr. Rev., June 1, 2005; 26(4): 504 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Dwyer, E. R. Bergert, M. K. O'Connor, S. J. Gendler, and J. C. Morris In vivo Radioiodide Imaging and Treatment of Breast Cancer Xenografts after MUC1-Driven Expression of the Sodium Iodide Symporter Clin. Cancer Res., February 15, 2005; 11(4): 1483 - 1489. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. C F Ferreira, L. P Lima, R. L Araujo, G. Muller, R. P Rocha, D. Rosenthal, and D. P Carvalho Rapid regulation of thyroid sodium-iodide symporter activity by thyrotrophin and iodine J. Endocrinol., January 1, 2005; 184(1): 69 - 76. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Trouttet-Masson, S. Selmi-Ruby, F. Bernier-Valentin, V. Porra, N. Berger-Dutrieux, M. Decaussin, J.-L. Peix, A. Perrin, C. Bournaud, J. Orgiazzi, et al. Evidence for Transcriptional and Posttranscriptional Alterations of the Sodium/Iodide Symporter Expression in Hypofunctioning Benign and Malignant Thyroid Tumors Am. J. Pathol., July 1, 2004; 165(1): 25 - 34. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. L. Wapnir, M. Goris, A. Yudd, O. Dohan, D. Adelman, K. Nowels, and N. Carrasco The Na+/I- Symporter Mediates Iodide Uptake in Breast Cancer Metastases and Can Be Selectively Down-Regulated in the Thyroid Clin. Cancer Res., July 1, 2004; 10(13): 4294 - 4302. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lacroix, T. Pourcher, C. Magnon, N. Bellon, M. Talbot, T. Intaraphairot, B. Caillou, M. Schlumberger, and J.-M. Bidart Expression of the Apical Iodide Transporter in Human Thyroid Tissues: A Comparison Study with Other Iodide Transporters J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1423 - 1428. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. De la Vieja, C. S. Ginter, and N. Carrasco The Q267E mutation in the sodium/iodide symporter (NIS) causes congenital iodide transport defect (ITD) by decreasing the NIS turnover number J. Cell Sci., February 15, 2004; 117(5): 677 - 687. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A.-C. Gerard, C. Daumerie, C. Mestdagh, S. Gohy, C. de Burbure, S. Costagliola, F. Miot, M.-C. Nollevaux, J.-F. Denef, J. Rahier, et al. Correlation between the Loss of Thyroglobulin Iodination and the Expression of Thyroid-Specific Proteins Involved in Iodine Metabolism in Thyroid Carcinomas J. Clin. Endocrinol. Metab., October 1, 2003; 88(10): 4977 - 4983. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Braga-Basaria and M. D. Ringel Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer J. Clin. Endocrinol. Metab., May 1, 2003; 88(5): 1947 - 1960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. L. Wapnir, M. van de Rijn, K. Nowels, P. S. Amenta, K. Walton, K. Montgomery, R. S. Greco, O. Dohan, and N. Carrasco Immunohistochemical Profile of the Sodium/Iodide Symporter in Thyroid, Breast, and Other Carcinomas Using High Density Tissue Microarrays and Conventional Sections J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1880 - 1888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Dohan, A. De la Vieja, V. Paroder, C. Riedel, M. Artani, M. Reed, C. S. Ginter, and N. Carrasco The Sodium/Iodide Symporter (NIS): Characterization, Regulation, and Medical Significance Endocr. Rev., February 1, 2003; 24(1): 48 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Taki, T. Kogai, Y. Kanamoto, J. M. Hershman, and G. A. Brent A Thyroid-Specific Far-Upstream Enhancer in the Human Sodium/Iodide Symporter Gene Requires Pax-8 Binding and Cyclic Adenosine 3',5'-Monophosphate Response Element-Like Sequence Binding Proteins for Full Activity and Is Differentially Regulated in Normal and Thyroid Cancer Cells Mol. Endocrinol., October 1, 2002; 16(10): 2266 - 2282. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J.-K. Chung Sodium Iodide Symporter: Its Role in Nuclear Medicine J. Nucl. Med., September 1, 2002; 43(9): 1188 - 1200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Tonacchera, P. Viacava, P. Agretti, G. de Marco, A. Perri, C. di Cosmo, M. de Servi, P. Miccoli, F. Lippi, A. G. Naccarato, et al. Benign Nonfunctioning Thyroid Adenomas Are Characterized by a Defective Targeting to Cell Membrane or a Reduced Expression of the Sodium Iodide Symporter Protein J. Clin. Endocrinol. Metab., January 1, 2002; 87(1): 352 - 357. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |
